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Abstract 
BACKGROUND: OSPL-502 is a new potential medicinal drug which stimulates a cognitive function. It is 
necessary to reveal clinical manifestations of its general toxic effect and determine organs that are most heavily 
affected by this pharmacological substance. 
AIMS: To describe and estimate clinical and histopathological changes in the organism of experimental animals in 
response to the repeated administration of pharmacological substance OSPL-502.  
MATERIAL AND METHODS: The study was conducted by the OECD Guidelines (Test No. 407) on Sprague-
Dawley rats. The drug was administered at the dose of 20, 60 and 180 mg/kg. 
RESULTS: The repeated doses of OSPL-502 have not caused any toxic effects on the growth of body weight, 
food and water consumption of the tested animals, or affected the musculoskeletal system and exploratory 
behaviour of the rats in the doses of 20 and 60 mg/kg. The dose of 180 mg/kg (1800 times larger than the 
therapeutic dose) has shown clinical signs of toxicity in females but has not resulted in the death of the animals. 
Due to morphological methods, we have found histostructural changes in the liver, kidneys and adrenal glands of 
the rats that were treated with the test substance in the maximum dose. These changes are reversible and reduce 
within 14 days after the admission of the studied substances is cancelled. 
CONCLUSION: OSPL-502 at the dose of 180 mg/kg has a weakly pronounced toxic effect, the dose of 60 mg/kg 
is the threshold, and that of 20 mg/kg is no-observable-adverse-effect-level (NOAEL); the liver, kidneys and 
adrenal glands can be considered target-organs for the tested substance. 
 
 
 
 
 
 
 
 
 
 
 
Introduction 
 
According to epidemiological data, at least 
50% of people over 65 years old have cognitive 
disorders of different intensities, and the risk of such 
disorders increase with age. Upward of 100 different 
neurological disorders are accompanied by cognitive 
dysfunctions which, in some cases, develop into 
dementia. The latest population studies demonstrate 
that there are about 46 million people living with 
dementia, with 50-70% of them diagnosed with 
Alzheimer's disease [1]. In 2006, there were about 15-
20 million patients [2]. According to the estimates 
provided by the Alzheimer's Association (2016), 5.4 
million Americans have Alzheimer's disease [3].  
These facts make it vital to search for, 
synthesise and study pharmacological properties of 
substances which can compensate neurological 
deficits and possess neuroprotective properties.  
It is known that glutamate receptors (AMPA 
and NMDA) play an important role in the formation of 
memory, which is one of the most important cognitive 
functions. The stimulation of AMPA-receptors 
improved the memory process [4]. Some substances 
that are modulators of AMPA receptors (including 
derivatives of N, N’-substituted 3,7-
diazabicyclo[3.3.1]nonanes), which has 
neuroprotective and cognitive-stimulating effects [5] 
[6], have been discovered and studied relatively 
recently [7] [8]. 
Basic Science 
_______________________________________________________________________________________________________________________________ 
 
_______________________________________________________________________________________________________________________________ 
1582                                                                                                                                                                                              https://www.id-press.eu/mjms/index 
 
OSPL-502 is a new derivative of N,N’-
substituted 3,7-diazabicyclo[3.3.1]nonanes and is a 
highly active positive modulator of АМРА-receptors. It 
is a new potential medicinal drug from the 
pharmacotherapeutic group of nootropics. Since 
OSPL-502 should be used as a medicinal drug, it is 
necessary to reveal clinical manifestations of its 
general toxic action in case of repeated administration 
and determine organs and organismal systems that 
are most heavily affected by this pharmacological 
substance to estimate the safety of this potential 
medicinal drug. 
Considering the data mentioned above, the 
current study aims to characterise and estimate 
clinical and pathological changes in the organism of 
experimental animals in response to the repeated 
administration of pharmacological substance OSPL-
502.  
In this regard, we planned to study clinical 
and morphofunctional changes of internal organs and 
the degree of reversibility of discovered changes after 
repeated oral administration of OSPL-502 to Sprague-
Dawley rats of both sexes. 
 
 
Material and Methods 
 
The study was conducted by the OECD 
Guidelines (Test No. 407: Repeated Dose 28-day Oral 
Toxicity Study in Rodents). Тhe tested, and control 
substances were administered to animals on a daily 
basis seven days a week within 28 days, which is in 
strict compliance with the research protocol. The 
substance administration into the stomach was 
provided by a probe at the same time before noon. 
The volume of the administered drug did not exceed 
10 ml/kg of the animal's weight.  
The volume and concentration of the 
administered pharmacological substance solution 
were daily corrected in response to mass body gain to 
maintain a constant dose of the substance in 
necessary proportions to the body mass of a growing 
animal. The drug was administered at the dose of 20, 
60 and 180 mg/kg, and the control animals were 
administered with a dispersion medium in the same 
volume.  
We used 10 animals (five female and five 
male) at each dose level and control. The satellite 
group of ten animals (five per sex) is used in control 
and the top dose group for observation of reversibility, 
persistence, or delayed the occurrence of toxic 
effects, for at least 14 days post-treatment (Table 1). 
The necropsy was performed in 24 hours after the end 
of treatment for the main groups (40 animals) and 14 
days later for satellite groups (20 animals). 
 
Table 1: Description of the study group 
Group / Dose 
Male Female 
The 
numerical 
indexes of 
animals 
The volume for 
administration 
(ml/kg) 
The 
concentration 
of a 
substance 
(mg/ml) 
The 
numerical 
indexes of 
animals 
The volume for 
administration 
(ml/kg) 
The 
concentration 
of a substance 
(mg/ml) 
1 / control 11-20 1.6 - 11-20 2.8 - 
2 / 20 mg/kg 21-25 1.6 12.4 21-25 2.8 7.7 
3 / 60 mg/kg 31-35 1.6 37.9 31-35 2.8 22.3 
4 / 180 mg/kg 41-50 1.6 109.4 41-50 2.8 64.4 
 
To conduct this research, we used animal 
species Rattus spp. (Sprague-Dawley rats: males and 
females which have never given birth or been 
pregnant) at the age of five weeks, (101 ± 2 gramme 
of body weight in female, 139 ± 2 gramme of body 
weight in male) received from a licensed source which 
has a valid АААLАС accreditation (Research and 
Production Enterprise “Laboratory animals farm”, 
Branch of the Institute of Bio-Organic Chemistry, the 
Russian Academy of Science, Moscow Region, 
Pushchino). Before the experiment, the animals were 
quarantined in cages for five days to adapt to group 
housing conditions. The care and keeping of the rats 
and all procedures with them were done in a vivarium 
of IPAC RAS (Institute of Physiologically Active 
Compounds of the Russian Academy of Science) 
strictly following the current ethical norms and 
regulations according to the research protocol and 
regulatory documents [9] [10] [11]. 
The animals were housed in groups of three 
in ventilated microisolator units One Cage 2100 (Lab. 
Products Inc., the USA) on the flooring LIGNOCEL 
Rinofix МК 2000 (JRS, Germany). In the animal 
housing rooms, we used the “day-night” lighting 
regime (12-hour cycle) and controlled the environment 
(temperature 18-25°С; relative humidity 30-70%). 
We fed the animals with standard sterile 
granulated compound feeding stuff for SPF animals 
entitled “Chara” (ООО “MultiTorg”, Russia) which was 
balanced in nutrients and vitamins, and autoclaved at 
121°С. The control over the autoclave functioning in 
feeding stuff sterilisation was performed using 
dipsticks in every cycle of autoclaving. The rats were 
given autoclaved water for drinking which had 
undergone additional purification against excessive 
salt and ferrous ions. The food and water were given 
to the rats without any restrictions. 
Throughout the research, we were registering 
clinical signs of intoxication, body mass and food 
consumption. At the same time, we were recording 
effects of the tested substance on locomotor activity, 
muscle strength, and orienting behaviour through 
special physiological tests. We also carried out the 
ophthalmological examination.  
OSPL-502 is a derivative of N,N’-substituted 
3,7-diazabicyclo[3.3.1] nonanes (3,7-bis (1,3-
benzodioxol-5- carbonyl)-1,5-dimethyl-3,7- 
diazabicyclo [3.3.1]nonane-9-OH) and is a highly 
active positive modulator of АМРА-receptors which 
synthesis in IPAC RAS and has neuroprotective and 
cognitive-stimulating effects [5] [6] [12] (Figure1). The 
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pharmacological substance is crystals of white colour 
which are insoluble in water but well soluble in organic 
solvents. The substance purity is > 95%.  
 
Figure 1: The structural formula of the OSPL-502 
 
Doses were prepared by a provisor on a daily 
basis just before the administration. The 
administration solutions were the tested substance 
suspended in a dispersion medium of 1% starch gel 
with distilled water. The dose calculation, as well as 
the regime and duration of the drug administration, 
were done according to the current regulating 
documents [13] [14] [15] [16] [17] and results of the 
previous research [18]. 
In 24 hours after the final administration of the 
substance (main groups of animals) and 14 days of 
the recovery period (satellite groups of animals), the 
animals underwent СO2-euthanasia with the following 
exsanguinating using blood draw from the inferior 
vena cava. Then we provided the complete 
examination of external conditions of a body and 
internal organs. During the necropsy, all changes in 
organs and tissues were registered. Also, brains, 
thyroid glands, hearts, lungs, thymus, spleens, livers, 
kidneys, bladders, stomachs, duodenum, colons, 
adrenal glands and gonads were taken for histological 
tests from each animal. 
The biomaterial for the pathomorphological 
study was kept in 10% neutral formalin (pH 7.4). 
Processing, embedding, microtomy, and staining of 
specimens was done according to standard 
techniques [19] [20] with some alterations. The organ 
slices were put into standard marked cassettes for 
further procedures.  
The processing of samples with an 
embedding medium was carried out using an 
automatic tissue processor Leica ASP 200S (Leica, 
Germany). After the preparation tissue samples were 
embedded into paraffin wax using tissue embedding 
system Leica EG1160 and then each block was cut by 
motorised rotary microtome Leica RM 2265 with 
microtome blades A35 (Feather, Japan). The 
produced standard cross sections five microns thick 
were placed on slides of common thickness (Menzel-
Glazer, Germany) and stained by haematoxylin and 
eosin. Staining of all the samples was simultaneously 
provided by multicoloured stainer Leica ST5020 
Multistainer in automatic mode. The stained samples 
were covered by standard coverslips.  
The further morphological analysis of the 
slides was provided using light microscopes Leica 
CME (Leica, Germany) and Micros MC100 (XP 5MP) 
(Micros, Austria). Concurrently, we used computer 
image analysis program Microvisible (Image 
Analyzing Software v. 1.11.10) together with Freeware 
Image Tool (the USA, University of Texas) calibrated 
by a stage micrometre for transmitted light OMP with 
spacing between tick marks equal to 0.005mm. 
The study was carried out by the Directive 
2010/63/EU of the European Parliament and Council 
(2010) on the protection of animals used for scientific 
purposes [21] and with The Guide for the Care and 
Use of Laboratory Animals [10] [11]. The research 
protocol was approved by the Ethics Committee of 
IPAC RAS on August 15, 2012 (Protocol No. 8). 
Group arithmetic means (M) and standard 
deviation (SD) were calculated for quantitative data. 
The statistical analysis was performed with program 
Statistic Base for Windows on Russian version 6.4. 
Male and female rates were tested independently. 
Differences were detected when a significant point 
was р < 0.05, tendencies were found when a 
significant point was р < 0.1 using the Student's t-test 
for independent samples and the Mann-Whitney 
nonparametric test. 
 
 
Results  
 
Throughout the research, the survival rate of 
the animals was 100% which proves the accuracy of 
the chosen dose regimes. The general state of health 
of the animals receiving the tested substance was 
also satisfactory. Intoxication manifestations differed 
depending on the animal’s sex.  
The retardation in mass body gain could be 
seen in female rats when the maximum dose of the 
tested substance was administered starting from the 
seventh day of the experiment. This retardation 
(averagely by 7%) remained within the whole period of 
the pharmacological substance administration.  
In 14 days after the substance administration, 
the mass body gain of all experimental groups 
receiving the maximum dose did not differ from that of 
the control group (Figures 2 and 3). The tested 
substance given in three different doses did not cause 
any significant effect on the animals' feed and water 
consumption. 
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Figure 2: The mass body gain in the female rats during the 
experiment (n = 5) 
 
We have found no locomotive system 
disturbances. The female rats administered the tested 
substance at the dose of 60 mg/kg were able to hang 
on the cage with increased strength. After the 28-day 
period of the drug administration, the orienting 
behaviour of both male and female rats in 
experimental groups was not different from the 
orienting behaviour of rats in the control group.  
 
Figure 3: The mass body gain in the male rats during the 
experiment (n = 5) 
 
The ophthalmological examination showed no 
exophthalmos, sclera reddening, corneal and lens 
opacity or any other changes in the retina. The 
pupillary light reflex retained. 
In two weeks after the withdrawal of the 
pharmacological substance OSPL-502, no clinical 
signs of intoxication were found that can indicate the 
absence of cumulative properties in the tested 
pharmacological substance. 
The animals’ necropsy showed no 
haemorrhages, visible pathological changes of 
internal organs, etc. The microstructure of the brain, 
heart, thymus, spleen, lungs, thyroid glands and 
bladder also corresponded to the norms. We have 
revealed no pathological changes in these organs 
related to the toxic influence of the substance. 
There were no macroscopic signs of mucous 
degeneration, ulcerations and necrosis in the stomach 
(where the substance was administrated to) of the 
animals receiving pharmacological substance OSPL-
502 at the doses of 20, 60 and 180 mg/kg. The 
histologic structure of a stomach wall of the animals in 
the control group and the animals receiving 
pharmacological substance OSPL-502 at the doses 
20, 60 and 180 mg/kg intragastrically corresponds to 
the norm, i.e. all four envelopes of the alimentary duct 
(mucous, submucous, muscular and serous) have a 
typical structure with no signs of degeneration or 
necrosis. Also, no ulcerogenic effect was detected as 
a result of the drug administration. The data 
mentioned above indicates the absence of the toxic 
influence on stomach walls during the 28-day 
administration of the tested substance. The structure 
of the duodenum wall showed no pathological 
changes caused by the drug influence. This organ had 
a typical structure with four envelopes, including the 
mucous, submucous, muscular and serous. We have 
also found no signs of epithelium necrosis.  
Duodenal glands had a typical structure. The 
insignificant plethora of microcirculatory vessels was 
detected. The colons of both male and female rats 
receiving the intragastrical administration of the tested 
substance at the doses of 20, 60 and 180 mg/kg had 
a typical structure and were not different from the 
structure of the colon of the rats in the control group. 
No signs of degeneration or necrosis were found. 
Inflammatory changes were absent. Therefore, OSPL-
502 at the tested doses produces no effect on walls of 
the digestive tract of the tested rats. 
The list structure of adrenal glands samples of 
the intact animals and the animals receiving OSPL-
502 was unharmed. In the studied samples, the cortex 
was distinguished from the medulla, the border 
between them was clear, but the latter was not always 
visible in all the cross-sections. There were cells with 
hydropic degeneration (from a small number of cells 
to moderate) in the upper third of the zona facilitate of 
the suprarenal cortex of all the animals. Nearly all 
cross-sections demonstrated cell clusters with small 
oval nuclei and oxyphilic cytoplasm. We have noted 
the moderate defatting of suprarenal cortex cells 
cytoplasm. The cells deprived of lipids were clustered 
in the form of triangular cords which started from the 
region where the zona glomerulosa bordered the zona 
fasciculata and then went down to the reticular zone. 
The zona reticularis and medulla were largely 
vascularized. The noted changes were reversible and 
reduced in 14 days after the substance was 
withdrawn. The histostructure of the adrenal glands of 
the animals receiving ОSPL-502 at the doses of 20 
and 60 mg/kg was not much different from that of the 
animals in the control group. The histostructure of 
adrenal glands of the female rats receiving OSPL-502 
at the dose of 180 mg/kg had more acute changes in 
comparison to the rats in the control group. The cells 
with signs of hydropic degeneration were located 
diffusely and mainly in the upper third of the zona 
fasciculate (Figure 4). 
The morphological examination of the liver 
and kidneys has shown some morphofunctional 
changes. 
The histologic structure of the liver in the rats 
receiving ОSPL-502 at the doses of 20 and 60 mg/kg 
was not different from that of the intact rats, i.e. the 
structure of the lobules with radially arranged plates of 
 Zhuchkov et al. Clinical and Morphological Aspects in Assessing the Safety of OSPL-502 
_______________________________________________________________________________________________________________________________ 
_______________________________________________________________________________________________________________________________ 
Open Access Maced J Med Sci. 2018 Sep 25; 6(9):1581-1587.                                                                                                                                                  1585 
 
hepatocytes was visible with no signs of fibrosis, 
infiltrates, etc. Hepatocytes were of a regular size and 
shape. However, there were single cells with signs of 
degeneration of different degrees (to the extent of 
hydropic). The hepatocytes nuclei were normochromic 
without pathological changes.  
 
Figure 4: A fragment of the rat’s adrenal glands administered with 
180mg/kg body weight of OSPL-502. Staining with hematoxylin and 
eosin. Magnification x200 showing the cells deprived of lipids and 
the cells with hydropic degeneration (with points) 
 
The intralobular sinusoids were without 
changes; other vascular system components were 
also in the same conditions. The female rats receiving 
ОSPL-502 at the dose of 180 mg/kg intragastrically 
had an increased number of degenerated hepatocytes 
in comparison to the control group. There were signs 
of regeneration processes activation which manifested 
itself by an increased number of immature 
hepatocytes radially moving down along the lobules in 
periportal areas and the region of terminal plates. We 
should note that these changes were reversible and 
were not found in the animals in after the 14-day 
substance administration withdrawal, or if the dose of 
the administered substance was 20 and 60 mg/kg 
(Figure 5). 
 
Figure 5: A fragment of the rat’s liver administered with 180mg/kg 
body weight of OSPL-502. Staining with hematoxylin and eosin. 
Magnification x400. Showing the immature hepatocytes (with 
points) 
The rats from intact groups and the rats 
receiving the substance at the doses of 20 and 60 
mg/kg had no differences in the histostructure of their 
kidneys. The kidney parenchyma had a typical 
structure; renal corpuscles were slightly increased, 
though, their histological structure was without any 
changes. Glomerular capillaries were filled with blood, 
the capsule of glomerulus was without changes. 
There were single shrunken and obsolete glomerulus 
(one or two in a cross-section).  
 
Figure 6: A fragment of the rat’s kidney administered with 180mg/kg 
body weight of OSPL-502. Staining with hematoxylin and eosin. 
Magnification x200. Showing the tubules with albuminous and 
hydropic degeneration 
 
Nephron tubules remained unchanged, 
though, there were single tubules with signs of 
hydropic degeneration, especially in the subcapsular 
area. The medullary substance of kidneys was without 
changes. The female rats receiving ОSPL-502 at the 
dose of 180mg/kg intragastrically had most of their 
renal corpuscles unchanged, their glomerular 
capillaries were filled with blood, and the glomerular 
capsule was without changes (Figure 6 and 7). 
 
Figure 7: A fragment of the rat’s kidney administered with 180 
mg/kg body weight of OSPL-502. Staining with hematoxylin and 
eosin. Magnification x400. Showing the tubules with albuminous 
degeneration (with points) 
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In half of the cases, there were tubules with 
albuminous and hydropic degeneration in cortical and 
medullary substances with some desquamation of 
tubules epithelium. There was no swelling of the 
interstitium. Within 14 days after the withdrawal of the 
substance administration the kidney structure of the 
animals in experimental groups was the same as that 
in the control group. 
 
 
Discussion 
 
The results of the undertaken study indicate 
mild morphofunctional changes in the liver and 
kidneys of the female rats receiving OSPL-502 at the 
dose of 180 mg/kg, which exceeds the therapeutic 
dose by 1800 times. The liver had signs of 
regeneration processes activation which manifested 
itself in the increase of immature hepatocytes radially 
moving down along the lobules in periportal areas and 
the region of terminal plates. Their kidneys had single 
tubules with albuminous and hydropic degeneration in 
cortical and medullary substances. It is necessary to 
denote that these changes were reversible and could 
not be found in the animals after the 14-day 
substance administration withdrawal of the dose of 20 
and 60 mg/kg. Therefore, the noted changes are 
reversible which corresponds to the known data [22]. 
Histostructural changes in adrenal glands of the rats 
receiving a maximum dose (the moderate defatting of 
cytoplasm of suprarenal cortex cells, mild 
degenerative processes) can either indicate that the 
pharmacological substance has a very weak toxic 
effect, or be a response to the stress caused by the 
long-time intragastric administration of the tested 
substance. We should note that morphofunctional 
changes are expressed mildly; they are not 
widespread and appear in both control and 
experimental groups. The changes mentioned above 
seem to be a result of tension as a response to the 
long-time external influence accompanied by stress 
which can lead to a decrease in cortisol level and 
signs of suprarenal cortex insufficiency [23] [24]. The 
noted changes are reversible and reduce within 14 
days after the substance administration is withdrawn. 
The research results are comparable with another 
study [18] and literature data about the toxicity of N, 
N’- substituted 3,7-azabicyclo[3.3.1]nonanes [5] [6] 
[7]. 
We can conclude that the repeated doses of 
OSPL-502 have not shown any toxic effects on the 
growth of body weight, food and water consumption of 
the tested animals or affected the musculoskeletal 
system and exploratory behaviour of the rats in doses 
of 20 and 60 mg/kg. The dose of 180 mg/kg (1800 
times larger than the therapeutic dose) resulted in 
only clinical signs of toxicity in the female rats but did 
not cause the animals’ death. We have only found 
histostructural changes using morphological methods 
in the liver, kidneys and adrenal glands of the rats 
treated to the test substance in the maximum dose. 
These changes are reversible and reduce within 14 
days after the cancellation of the studied substances. 
Therefore, our studies have revealed that the target 
organs for the test substances are the liver, kidneys 
and adrenal glands.  
The identified changes are reversible after the 
withdrawal of the substance; OSPL-502 at the dose of 
180 mg/kg has a weak toxic effect, the dose of 60 
mg/kg is the threshold, and 20 mg/kg is no-
observable-adverse-effect-level (NOAEL). 
In conclusion, the female rats are more 
sensitive to the tested substance than the male ones 
when it comes to the repeated oral administration of 
the substance, but this gender difference is evident 
only in case of the maximum tested dose of 180 
mg/kg. Considering the obtained data, the liver, 
kidneys and adrenal glands can be regarded as 
target-organs for the tested substance. The dose of 
20 mg/kg exceeding the therapeutic dose by 200 
times is non-toxic (NOAEL-No-Observable-Adverse-
Effect-Level). Morphofunctional changes in the liver, 
kidneys and adrenal glands are reversible and reduce 
within 14 days after the substance withdrawal.  
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